SiVEC Biotechnologies Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$3.3M
- Investors
-
8
SiVEC Biotechnologies General Information
Description
Developer of a live biotherapeutic delivery platform designed to advance nucleic acid and gene therapies into clinical trials. The company's delivery system uses genetically engineered bacteria as shuttle vehicles for safe, tissue-targeted delivery of therapeutics, including small interfering ribonucleic acid, micro ribonucleic acids, clustered regularly interspaced short palindromic repeats, and proteins, allowing the nucleic acid and gene editing therapies, enabling physicians with technology to address several therapeutic needs.
Contact Information
Website
www.sivecbiotechnologies.comCorporate Office
- 1505 West Mulberry Street
- Fort Collins, CO 80521
- United States
Corporate Office
- 1505 West Mulberry Street
- Fort Collins, CO 80521
- United States
SiVEC Biotechnologies Timeline
SiVEC Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Seed Round | 17-Sep-2025 | $3.3M | Completed | Pre-Clinical Trials | ||
| 9. Accelerator/Incubator | 01-Jan-2025 | Completed | Pre-Clinical Trials | |||
| 8. Grant | 18-May-2023 | Completed | Pre-Clinical Trials | |||
| 7. Accelerator/Incubator | 19-Apr-2022 | Completed | Pre-Clinical Trials | |||
| 6. Grant | 17-Sep-2021 | Completed | Pre-Clinical Trials | |||
| 5. Grant | 11-May-2020 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 20-Aug-2018 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 01-Jan-2018 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 01-Mar-2016 | $22K | Completed | Pre-Clinical Trials | ||
| 1. Accelerator/Incubator | 01-Jan-2016 | Completed | Pre-Clinical Trials |
SiVEC Biotechnologies Patents
SiVEC Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022286964-A1 | Bacterial delivery of antibodies, antibody derivatives, and polypeptides to eukaryotic cells | Pending | 02-Jun-2021 | ||
| CA-3220834-A1 | Bacterial delivery of antibodies, antibody derivatives, and polypeptides to eukaryotic cells | Pending | 02-Jun-2021 | ||
| WO-2022256519-A1 | Bacterial delivery of antibodies, antibody derivatives, and polypeptides to eukaryotic cells | Inactive | 02-Jun-2021 | ||
| AU-2021206307-A1 | A microbial system for production and delivery of eukaryote-translatable mrna to eukarya | Pending | 11-Jan-2020 | ||
| CA-3164395-A1 | A microbial system for production and delivery of eukaryote-translatable mrna to eukarya | Pending | 11-Jan-2020 | C12N15/70 |
SiVEC Biotechnologies Signals
SiVEC Biotechnologies Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| William Taylor Nominees | Venture Capital | Minority | ||
| Springboard Enterprises | Accelerator/Incubator | |||
| State of Colorado | Government | |||
| California Life Sciences | Accelerator/Incubator | |||
| National Institute for Allergy and Infectious Disease | Government |
SiVEC Biotechnologies FAQs
-
When was SiVEC Biotechnologies founded?
SiVEC Biotechnologies was founded in 2016.
-
Where is SiVEC Biotechnologies headquartered?
SiVEC Biotechnologies is headquartered in Fort Collins, CO.
-
What is the size of SiVEC Biotechnologies?
SiVEC Biotechnologies has 5 total employees.
-
What industry is SiVEC Biotechnologies in?
SiVEC Biotechnologies’s primary industry is Drug Delivery.
-
Is SiVEC Biotechnologies a private or public company?
SiVEC Biotechnologies is a Private company.
-
What is SiVEC Biotechnologies’s current revenue?
The current revenue for SiVEC Biotechnologies is .
-
How much funding has SiVEC Biotechnologies raised over time?
SiVEC Biotechnologies has raised $3.3M.
-
Who are SiVEC Biotechnologies’s investors?
William Taylor Nominees, Springboard Enterprises, State of Colorado, California Life Sciences, and National Institute for Allergy and Infectious Disease are 5 of 8 investors who have invested in SiVEC Biotechnologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process